Semaglutide for weight loss: what the clinical evidence actually shows

What the STEP trials established about semaglutide and weight loss

The STEP programme is the body of evidence regulators and NICE relied on when approving semaglutide for weight management in the UK. STEP 1, the pivotal trial, enrolled almost 2,000 adults without diabetes who had a BMI of 30 or above (or 27 or above with a weight-related condition). Over 68 weeks, participants taking 2.4mg semaglutide weekly alongside lifestyle counselling lost an average of around 15% of their starting weight, compared with roughly 2.4% in the placebo group. That gap is large enough to matter clinically: it translates to meaningful reductions in blood pressure, waist circumference and markers linked to cardiovascular risk.

NICE formally recommended semaglutide (Wegovy) for NHS use in 2023 under technology appraisal TA875, but attached conditions: use within a specialist weight management service, for a maximum of two years, and only if at least 5% of body weight has been lost after six months at the maintenance dose. That two-year NHS ceiling does not apply to private prescribing, though the clinical principle (assessing whether treatment is still working) remains sound and is built into how responsible prescribers manage ongoing care.

A newer formulation, the oral tablet, was approved by the MHRA on 11 June 2026, with phase 3 data showing around 13.6% average weight loss over 64 weeks. Among participants who stayed fully adherent, the figure rose to roughly 17%. If you are curious whether an oral form of semaglutide might suit you better than an injection, that is exactly the kind of preference a prescriber can factor into a recommendation.

How semaglutide actually produces weight loss in the body

Semaglutide is a GLP-1 receptor agonist, it mimics a gut hormone (glucagon-like peptide-1) that the body releases naturally after eating. Activating GLP-1 receptors in the brain reduces appetite and increases the feeling of fullness; in the stomach it slows gastric emptying, so food stays with you longer. The combined effect is that most people find they feel satisfied eating less, and their interest in snacking between meals falls noticeably.

A common question is whether the weight comes back when treatment stops. Trial data suggest that, without continued treatment and sustained lifestyle changes, weight tends to return over one to two years. That is not a failing of the medicine, it reflects the biology of obesity, which the NHS describes as a complex condition driven by hormonal, genetic and environmental factors rather than willpower alone. GLP-1 medicines work with that biology rather than against it.

For a more detailed explanation of the appetite and metabolic pathways involved, the page on how semaglutide causes weight loss goes into the physiology step by step. The short version: it is not stimulating your metabolism or burning fat directly, it is changing the signals that tell you how hungry you are.

Who semaglutide is licensed for, and the side effects worth knowing

The UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, things like high blood pressure, dyslipidaemia, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, reflecting differences in disease risk at equivalent BMIs. BMI alone does not guarantee a prescription: your prescriber reviews the full picture, including any medicines you already take and conditions that might affect suitability.

Side effects are mainly gastrointestinal, nausea, loose stools, constipation and indigestion are the most commonly reported, particularly in the early weeks or after a dose increase. For most people they ease within a couple of weeks. Rarer but more serious effects include acute pancreatitis: if you develop severe stomach pain that spreads to the back, seek urgent medical help and do not wait to see whether it settles. You can report any suspected side effect through the MHRA Yellow Card scheme. Semaglutide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive, and it is not licensed for under-18s.

One thing worth doing before you read any further: check the GPhC register at pharmacyregulation.org/registers to confirm any online pharmacy you are considering is properly registered. It takes under a minute and removes a lot of uncertainty about whether what you are ordering is genuine.

How to access semaglutide for weight loss in the UK

There are two routes. NHS access via Wegovy exists but is limited to specialist weight management services, with eligibility criteria and waiting lists that vary considerably by area, and our page on how Wegovy works for weight loss explains what to expect from that process in practice. On the semaglutide near you page, we explain how NHS commissioning works across England, Scotland, Wales and Northern Ireland, where the thresholds and timelines differ.

The private route lets you access treatment without a referral and without a waiting list, provided a prescriber finds you clinically suitable. If you would like a thorough grounding in how semaglutide is used for weight loss, including dosing schedules and what clinical monitoring should look like, that page covers it in full. Legitimate private prices include the consultation, the prescription assessment and the medicine itself, any listing that does not account for clinical oversight is worth scrutinising.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. Not software, not a triage algorithm, a named clinician who reviews your answers the same day. For a closer look at how semaglutide works as a peptide-based treatment for weight loss, that page explains what sets this class of medicine apart from older approaches. If you are ready to find out whether semaglutide is right for you, check your eligibility with a free consultation.